Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression

Clinical Cancer Research

Volumn 19, Issue 3, 2013, Pages 699-709

  Lévesque, Éric ^a,b   Huang, Shu Pin ^c,d   Audet Walsh, Étienne ^a   Lacombe, Louis ^b   Bao, Bo Ying ^f,g   Fradet, Yves ^b   Laverdière, Isabelle ^a   Rouleau, Mélanie ^a   Huang, Chao Yuan ^h   Yu, Chia Cheng ^e   Caron, Patrick ^a   Guillemette, Chantal ^a  

^a Université Laval   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Department of Otorhinolaryngology Head and Neck Surgery   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ANDROSTERONE; ANDROSTERONE GLUCURONIDE; ESTRONE SULFATE; PRASTERONE SULFATE; UNCLASSIFIED DRUG;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; CYP17A1 GENE; CYP19A1 GENE; DISEASE COURSE; DISEASE MARKER; ESR1 GENE; ETHNIC GROUP; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HAPLOTYPE; HOMOZYGOSITY; HSD3B1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVE MASS SPECTROMETRY; SINGLE NUCLEOTIDE POLYMORPHISM; STEROID BLOOD LEVEL; STEROIDOGENESIS; TAIWANESE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; GONADAL STEROID HORMONES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; STEROIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873326768     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2812     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Globalcancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009;6: 76-85.
3. Horwitz EM. Prostate cancer: optimizing the duration of androgen deprivation therapy. Nat Rev Urol 2009;6:527-9.
4. Bianchini D, de Bono JS. Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer. Eur J Cancer 2011;47 Suppl 3: S189-94.
5. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.
6. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 2011;108:13728-33.
7. Sharifi N. The 5alpha-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer. J Invest Med 2012;60: 504-7.
8. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
9. Miller K. Words of wisdom. Re: antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Scher HI, Beer TM, Higano CS, et al. Prostate cancer foundation/department of defense prostate cancer clinical trials consortium. Eur Urol 2010;58: 464-5.
10. Payton S. Prostate cancer: MDV3100 has antitumor activity in castration-resistant disease. Nat Rev Urol 2010;7:300.
11. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.
12. Yap TA, Zivi A, Omlin A, de Bono JS. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8:597-610.
13. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2008;26:842-7.
14. Rasiah KK, Gardiner-Garden M, Padilla EJ, Moller G, Kench JG, Alles MC, et al. HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. Mol Cell Endocrinol 2009;301:89-96.
15. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2011;29:2565-73.
16. Nadeau G, Bellemare J, Audet-Walsh E, Flageole C, Huang SP, Bao BY, et al. Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. J Clin Endocrinol Metab 2011;96:E1550-7.
17. Audet-Walsh E, Bellemare J, Lacombe L, Fradet Y, Fradet V, Douville P, et al. The impact of germline genetic variations in hydroxysteroid (17-Beta) dehydrogenases on prostate cancer outcomes after prostatectomy. Eur Urol 2012;62:88-96.
18. Huang CN, Huang SP, Pao JB, Chang TY, Lan YH, Lu TL, et al. Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Ann Oncol 2012;23:707-13.
19. Audet-Walsh E, Bellemare J, Nadeau G, Lacombe L, Fradet Y, Fradet V, et al. SRD5A polymorphisms and biochemical failure after radical prostatectomy. Eur Urol 2011;60:1226-34.
20. Lepine J, Audet-Walsh E, Gregoire J, Tetu B, Plante M, Menard V, et al. Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocrinol Metab 2010;95: 2689-98.
21. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5.
22. Huang CN, Huang SP, Pao JB, Hour TC, Chang TY, Lan YH, et al. Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy. J Intern Med 2012;271:499-509.
23. Labrie F, Luu-The V, Lin SX, Simard J, Labrie C. Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol Metab 2000;11: 421-7.
24. Harkonen P, Torn S, Kurkela R, Porvari K, Pulkka A, Lindfors A, et al. Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state. J Clin Endocrinol Metab 2003;88: 705-12.
25. Elo JP, Harkonen P, Kyllonen AP, Lukkarinen O, Poutanen M, Vihko R, et al. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res 1997;57:3356-9.
26. Harkonen P, Kyllonen AP, Nordling S, Vihko P. Loss of heterozygosity in chromosomal region 16q24.3 associated with progression of prostate cancer. Prostate 2005;62:267-74.
27. Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, et al. Common structural and epigenetic changes in the genome of castration resistant prostate cancer. Cancer Res 2012; 72:616-25.
28. Sun T, Oh WK, Jacobus S, Regan M, Pomerantz M, Freedman ML, et al. The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prev Res (Phila) 2011;4:2044-50.
29. Adeniji AO, Twenter BM, Byrns MC, Jin Y, Chen M, Winkler JD, et al. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17beta-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. J Med Chem 2012;55:2311-23.
30. Chen M, Adeniji AO, Twenter BM, Winkler JD, Christianson DW, Penning TM. Crystal structures of AKR1C3 containing an N-(aryl) amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer. Bioorg Med Chem Lett 2012;22:3492-7.
31. Yamada T, Nakayama M, Shimizu T, Nonen S, Nakai Y, Nishimura K, et al. Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy. Int J Clin Oncol 2012 Jun 21. [Epub ahead of print].
32. Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D, et al. Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. Urology 2007;70:217-20.
33. Wright JL, Kwon EM, Lin DW, Kolb S, Koopmeiners JS, Feng Z, et al. CYP17 polymorphisms and prostate cancer outcomes. Prostate 2010;70:1094-101.
34. Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res 2007;13:2030-7.
35. Giton F, de la Taille A, Allory Y, Galons H, Vacherot F, Soyeux P, et al. Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa). J Steroid Biochem Mol Biol 2008;109:158-67.
36. Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, Kantoff PW, et al. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev 2010;19: 1871-8.
37. Li N, Dong J, Hu Z, Shen H, Dai M. Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010;121:177-84.